Prostate Cancer

>

Latest News

Previous results from the study found improvement in the primary end point of PSA-PFS with apalutamide in recurrent prostate cancer.
Apalutamide/ADT Displays Long-Term Efficacy in Recurrent Prostate Cancer

October 20th 2025

Previous results from the study found improvement in the primary end point of PSA-PFS with apalutamide in recurrent prostate cancer.

Findings from the PSMAddition trial support the benefit of the early addition of lutetium Lu 177 vipivotide tetraxetan in metastatic HSPC.
Radioligand Therapy Combo Boosts rPFS in PSMA+ Metastatic HSPC

October 19th 2025

Findings from the ENZARAD trial support adding enzalutamide to androgen deprivation therapy for those with positive lymph nodes.
Enzalutamide Combo Shows No MFS Improvement in Advanced Prostate Cancer

October 19th 2025

At 8 years follow-up, patients with recurrent prostate cancer in the enzalutamide/leuprolide arm had an OS rate of 78.9% vs 69.5% vs leuprolide alone.
Enzalutamide/Leuprolide Regimen Reduces Risk of Death in Prostate Cancer

October 19th 2025

Capivasertib plus abiraterone show consistent benefits across clinical end points in the phase 3 CAPItello-281 trial.
Capivasertib Combo Improves rPFS in PTEN-Deficient HSPC Population

October 19th 2025

Video Series
Video Interviews
Podcasts
1 expert in this video
1 expert in this video
1 expert in this video
AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.
Latest CME Events & Activities

More News